Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical CoBSP:TAKP34 64 EV-to-FCF is 17.04 as of Aug. 02, 2026, which is 11% below its 10-year median of 19.05. GuruFocus rates BSP:TAKP34 with a GF Score™ of 64/100 and a GF Value™ of R$74.26 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 571 Drug Manufacturers companies, Takeda Pharmaceutical Co ranks better than 54.82% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Takeda Pharmaceutical Co's Enterprise Value is R$429,773 Mil.
Takeda Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was R$25,226 Mil. Therefore, Takeda Pharmaceutical Co's EV-to-FCF for today is 17.04.
The historical rank and industry rank for Takeda Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
BSP:TAKP34'
s EV-to-FCF Range Over the Past 10 Years
Min: -155.73 Med: 19.05 Max: 88.68
Current: 18.83
During the past 13 years, the highest EV-to-FCF of Takeda Pharmaceutical Co was 88.68. The lowest was -155.73. And the median was 19.05.
BSP:TAKP34's EV-to-FCF is ranked better than 54.82% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.66
vs BSP:TAKP34: 18.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Takeda Pharmaceutical Co (BSP:TAKP34) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Takeda Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Takeda Pharmaceutical Co's share price for today is R$89.98.
Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1.743.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Takeda Pharmaceutical Co EV-to-FCF Related Terms
Takeda Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's EV-to-FCF falls into.
Takeda Pharmaceutical Co's current Enterprise Value is R$429,773 Mil.
Takeda Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$25,226 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (BSP:TAKP34) has a EV-to-FCF of 17.04 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Takeda Pharmaceutical Co and its competitors. This is 11% below median its historical median of 19.05. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #258 out of 571 companies in the Drug Manufacturers industry, placing it in the top 45.2%.
Is Takeda Pharmaceutical Co's EV-to-FCF too high?
Takeda Pharmaceutical Co's current EV-to-FCF of 17.04 is 11% below median its 10-year median of 19.05. The Drug Manufacturers industry median EV-to-FCF is 20.66. Takeda Pharmaceutical Co's value of 17.04 is 17.5% below this industry median. Based on the distribution chart, Takeda Pharmaceutical Co ranks #258 out of 571 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Takeda Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #258 out of 571 companies for EV-to-FCF. This puts Takeda Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 20.66. Takeda Pharmaceutical Co's value of 17.04 is 17.5% below this benchmark. While the company's 10-year median is 19.05 vs. the industry median of 20.66, Takeda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.66, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takeda Pharmaceutical Co's current EV-to-FCF of 17.04 is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Takeda Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takeda Pharmaceutical Co's current EV-to-FCF is 17.04, which is 11% below median its own 10-year median of 19.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (BSP:TAKP34) is currently considered Modestly Overvalued. The stock's GF Value™ is R$74.26, compared to a current price of R$89.98 — trading 21.2% above its estimated fair value. The current EV-to-FCF is 17.04, which is 11% below median its 10-year median of 19.05 and 17.5% below the Drug Manufacturers industry median of 20.66. Takeda Pharmaceutical Co's overall GF Score™ is 64/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Takeda Pharmaceutical Co (BSP:TAKP34), the current EV-to-FCF is 17.04 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (BSP:TAKP34) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of R$89.98 is trading 21.2% above its estimated GF Value™ of R$74.26.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for BSP:TAKP34:
EV-to-FCF: 17.04 (11% below median its 10-year median of 19.05)
GF Value™: R$74.26 vs. price of R$89.98 (21.2% above fair value)
Industry Position: 17.5% below the Drug Manufacturers median (#258 of 571)
No single metric tells the full story. See the BSP:TAKP34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
64GF Score
Get the complete analysis for BSP:TAKP34
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TAKP34 has been successfully added to your 
